Pulmonx Corporation
LUNG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $84 | $69 | $54 | $48 |
| % Growth | 22% | 28% | 10.8% | – |
| Cost of Goods Sold | $22 | $18 | $14 | $13 |
| Gross Profit | $62 | $51 | $40 | $36 |
| % Margin | 74% | 73.9% | 74.3% | 73.6% |
| R&D Expenses | $18 | $18 | $15 | $13 |
| G&A Expenses | $94 | $90 | $0 | $0 |
| SG&A Expenses | $102 | $95 | $83 | $70 |
| Sales & Mktg Exp. | $8 | $5 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $120 | $113 | $99 | $83 |
| Operating Income | -$58 | -$62 | -$59 | -$47 |
| % Margin | -68.9% | -90.2% | -109.3% | -97.7% |
| Other Income/Exp. Net | $2 | $2 | $0 | -$1 |
| Pre-Tax Income | -$56 | -$60 | -$59 | -$48 |
| Tax Expense | $1 | $1 | $0 | $0 |
| Net Income | -$56 | -$61 | -$59 | -$49 |
| % Margin | -67.3% | -88.6% | -109.8% | -100.5% |
| EPS | -1.44 | -1.6 | -1.59 | -1.35 |
| % Growth | 10% | -0.6% | -17.8% | – |
| EPS Diluted | -1.44 | -1.6 | -1.59 | -1.35 |
| Weighted Avg Shares Out | 39 | 38 | 37 | 36 |
| Weighted Avg Shares Out Dil | 39 | 38 | 37 | 36 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $2 | $0 |
| Interest Expense | $4 | $3 | $1 | $1 |
| Depreciation & Amortization | $2 | $2 | $2 | $1 |
| EBITDA | -$51 | -$55 | -$56 | -$47 |
| % Margin | -60.6% | -80.2% | -104.3% | -96.3% |